AR029916A1 - N-formil-n-hidroxi-ariloxi alquilaminas y metodos para tratar infecciones bacterianas - Google Patents

N-formil-n-hidroxi-ariloxi alquilaminas y metodos para tratar infecciones bacterianas

Info

Publication number
AR029916A1
AR029916A1 ARP010102092A ARP010102092A AR029916A1 AR 029916 A1 AR029916 A1 AR 029916A1 AR P010102092 A ARP010102092 A AR P010102092A AR P010102092 A ARP010102092 A AR P010102092A AR 029916 A1 AR029916 A1 AR 029916A1
Authority
AR
Argentina
Prior art keywords
carbons
optionally substituted
methods
bacterial infections
ariloxi
Prior art date
Application number
ARP010102092A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR029916A1 publication Critical patent/AR029916A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C239/00—Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
    • C07C239/08—Hydroxylamino compounds or their ethers or esters
    • C07C239/14—Hydroxylamino compounds or their ethers or esters having nitrogen atoms of hydroxylamino groups further bound to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

N-formil-N-hidroxi-ariloxi alquilaminas de formula (1), en donde X es O; n es un entero 1 o 2; Ar es un grupo arilo seleccionado entre el grupo que consta de azaindolilo, pirazinilo, isoxazolilo, oxazolilo, tiazolilo, isotiazolilo, imidazolilo e isoquinolinilo; de manera tal que que Ar puede estar sustituido opcionalmente con uno, dos o tres sustituyentes seleccionados entre el grupo que consta de alquilo o cicloalquilo opcionalmente sustituido de uno a nueve carbonos, halo, alcoxi de uno a nueve carbonos, hidroxi, amino, hidroxialquilo de uno a nueve carbonos, alcoxialquilo, en donde los grupos alquilo y alquileno son independientemente de uno a nueve carbonos, arilo opcionalmente sustituido o heteroarilo, carboxi y alcoxicarbonilo opcionalmente sustituidos. Tales compuestos son inhibidores de la péptido-desformilasa. También se dan a conocer métodos para tratar infecciones bacterianas.
ARP010102092A 2000-05-05 2001-05-03 N-formil-n-hidroxi-ariloxi alquilaminas y metodos para tratar infecciones bacterianas AR029916A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20194300P 2000-05-05 2000-05-05
US23808400P 2000-10-04 2000-10-04

Publications (1)

Publication Number Publication Date
AR029916A1 true AR029916A1 (es) 2003-07-23

Family

ID=26897227

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010102092A AR029916A1 (es) 2000-05-05 2001-05-03 N-formil-n-hidroxi-ariloxi alquilaminas y metodos para tratar infecciones bacterianas

Country Status (20)

Country Link
US (2) US6806369B2 (es)
EP (1) EP1283711B1 (es)
JP (1) JP2003532677A (es)
KR (1) KR20020093127A (es)
CN (1) CN1427721A (es)
AR (1) AR029916A1 (es)
AT (1) ATE389403T1 (es)
AU (1) AU2001261218A1 (es)
BR (1) BR0110206A (es)
CA (1) CA2408236A1 (es)
CZ (1) CZ20023618A3 (es)
DE (1) DE60133273T2 (es)
ES (1) ES2300330T3 (es)
HU (1) HUP0302505A2 (es)
IL (1) IL152638A0 (es)
MX (1) MXPA02010843A (es)
NO (1) NO20025281L (es)
NZ (1) NZ521560A (es)
PL (1) PL359865A1 (es)
WO (1) WO2001085170A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1383736B1 (en) * 2001-04-05 2009-06-17 Smithkline Beecham Corporation Peptide deformylase inhibitors
AU2002322035A1 (en) * 2001-06-05 2002-12-16 Smithkline Beecham Corporation Peptide deformylase inhibitors
WO2004052919A2 (en) * 2002-12-11 2004-06-24 Smithkline Beecham Corporation Peptide deformylase inhibitors
EP1683521A1 (en) * 2005-01-21 2006-07-26 Centre National De La Recherche Scientifique (Cnrs) Peptide deformylase inhibitors, their use, and pharmaceutical compositions containing the same
DE102005019181A1 (de) * 2005-04-25 2006-10-26 Novartis Ag Peptid-Deformylase (PDF) Inhibitoren 1
JP2008538776A (ja) * 2005-04-25 2008-11-06 ノバルティス アクチエンゲゼルシャフト ペプチド脱ホルミル酵素（ｐｄｆ）阻害剤として有用なイミダゾ［１，２−ａ］ピリジン誘導体
JP2008545765A (ja) * 2005-06-07 2008-12-18 ノバルティス アクチエンゲゼルシャフト ペプチドデホルミラーゼ（ｐｄｆ）阻害剤４
WO2007040289A1 (en) * 2005-10-05 2007-04-12 Promeditech Inc. Deformylase inhibitor, process for the preparation thereof, and composition comprising the same
KR100753796B1 (ko) * 2006-07-28 2007-08-31 주식회사 프로메디텍 데포르밀라제 저해제, 이의 제조방법, 및 이를 포함하는조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3282986A (en) * 1960-10-06 1966-11-01 Merck & Co Inc N-acylated hydroxamic acids and derivatives thereof
JP2559699B2 (ja) 1985-03-16 1996-12-04 ザ ウエルカム フアウンデ−シヨン リミテツド 新規なアリ−ル誘導体
GB8531838D0 (en) * 1985-12-30 1986-02-05 Wellcome Found Aryl derivatives
PL154186B1 (en) 1987-07-15 1991-07-31 Wellcome Found Method for manufacturing arylic derivatives of the hydroxamic acid
JP3662941B2 (ja) 1997-07-31 2005-06-22 アボツト・ラボラトリーズ マトリックスメタロプロテイナーゼのリバースヒドロキサメート阻害剤
US6235786B1 (en) 1997-08-06 2001-05-22 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
US6294573B1 (en) 1997-08-06 2001-09-25 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
DK1052984T3 (da) 1998-02-07 2004-09-20 Vernalis Oxford Ltd Antibakterielle midler
AR028075A1 (es) * 2000-05-05 2003-04-23 Smithkline Beecham Corp Inhibidores de la peptido-desformilasa
US20040034024A1 (en) 2001-05-04 2004-02-19 Aubart Kelly M Peptide deformylase inhibitors

Also Published As

Publication number Publication date
KR20020093127A (ko) 2002-12-12
CA2408236A1 (en) 2001-11-15
US20040053932A1 (en) 2004-03-18
ATE389403T1 (de) 2008-04-15
US7115605B2 (en) 2006-10-03
WO2001085170A9 (en) 2006-01-26
NZ521560A (en) 2004-05-28
AU2001261218A1 (en) 2001-11-20
NO20025281L (no) 2003-01-03
JP2003532677A (ja) 2003-11-05
DE60133273D1 (de) 2008-04-30
NO20025281D0 (no) 2002-11-04
WO2001085170A1 (en) 2001-11-15
CZ20023618A3 (cs) 2003-09-17
HUP0302505A2 (hu) 2003-12-29
EP1283711A4 (en) 2003-05-21
EP1283711A1 (en) 2003-02-19
DE60133273T2 (de) 2009-03-05
US6806369B2 (en) 2004-10-19
US20040192719A1 (en) 2004-09-30
BR0110206A (pt) 2003-01-28
MXPA02010843A (es) 2003-03-27
EP1283711B1 (en) 2008-03-19
IL152638A0 (en) 2003-06-24
ES2300330T3 (es) 2008-06-16
CN1427721A (zh) 2003-07-02
PL359865A1 (en) 2004-09-06

Similar Documents

Publication Publication Date Title
NO20062185L (no) Hepatitt C virus-inhibitorer
AR042851A1 (es) Acidos hidroxamicos inhibidores de histona desacetilasa
DE69420564D1 (de) Immunsuppressive und antiallergische verbindungen; z.b. n-(3-oxohexanoyl)-homoserinlacton
AR058569A1 (es) Inhibidores de histona desacetilasa para mejorar la actividad de agentes antifungicos
HRP20090627T1 (hr) Inhibitori hcv ns3 proteaze
NO20054195L (no) Isoksazolforbindelser som inhibitorer for varmesjokkproteiner
TR199800147T1 (xx) Farnesil transferaz inhibit�rleri olarak 4-merkaptopirolidin t�revleri.
CL2004000076A1 (es) Compuestos derivados de indol, inhibidores de polimerasa, sales; composicion farmaceutica que los comprende; procedimiento de preparacion de dichos compuestos; compuestos intermediarios; y uso del compuesto para tratar una infeccion causada por el vi
AR029916A1 (es) N-formil-n-hidroxi-ariloxi alquilaminas y metodos para tratar infecciones bacterianas
AR047683A1 (es) Pirazoles para el tratamiento de obesidad y trastornos psiquiatricos
ATE479667T1 (de) Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis
CO5251464A1 (es) Inhibidores de n-(5-(((5-alquil-2-oxazolil)metil)tio)-2- tiazolil)-carboxamida de cinasas dependientes de ciclina
CO6260074A2 (es) Compuestos de 5-(4-(halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones como inhibidores de cinasa
AR049487A1 (es) Compuestos de imidazol sustituidos
NO20060665L (no) N-substituerte pyrazolyl-amidyl-benzimidazolyl C-kit inhibitorer
CR10127A (es) Agente para la prevención o tratamiento de neuropatías (divisional exp. 7849)
NO20005237L (no) Heterocyklisk substituerte amider anvendt som calpain- inhibitorer
ES2188194T3 (es) 1,8-naftiridin-4(1h)-onas sustituidas como inhibidores de la fosfodiesterasa 4.
EA200100623A1 (ru) Кетолидные антибиотики
EP0670309A4 (en) RELATED TO PROLYE-ENDOPEPTIDASE INHIBITING ACTIVITY AND THEIR PHARMACEUTICAL USE.
EA200501730A1 (ru) Производные n-пирролидин-3-ил-амида в качестве ингибиторов обратного захвата серотонина и норадреналина
ATE476431T1 (de) Piperidin- und azetidinderivate als glyt1- inhibitoren
IL173819A0 (en) Compounds and methods for treating dyslipidemia
CO4950567A1 (es) Inhibidores de proteasas dores de proteasas.
WO2002028829A3 (en) Peptide deformylase inhibitors

Legal Events

Date Code Title Description
FA Abandonment or withdrawal